lonafarnib
Selected indexed studies
- Lonafarnib. (, 2012) [PMID:33560735]
- Lonafarnib: First Approval. (Drugs, 2021) [PMID:33590450]
- Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone. (J Cachexia Sarcopenia Muscle, 2025) [PMID:39686867]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lonafarnib. (2012) pubmed
- Lonafarnib: First Approval. (2021) pubmed
- Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone. (2025) pubmed
- Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor. (2024) pubmed
- Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein. (2024) pubmed
- Lonafarnib. (2021) pubmed
- Lonafarnib in cancer therapy. (2006) pubmed
- Lonafarnib for cancer and progeria. (2012) pubmed
- Lonafarnib-A new member of the Delta Force? (2022) pubmed
- Baricitinib and Lonafarnib Synergistically Target Progerin and Inflammation, Improving Lifespan and Health in Progeria Mice. (2025) pubmed